Wedbush initiated coverage of Sarepta (SRPT) with an Outperform rating and $32 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta Grants CEO Equity Awards After Eight Years
- Needham starts Solid Biosciences at Buy on opening in DMD market
- Sell Rating for Sarepta Therapeutics Due to Risks in ENDEAVOR Study and Expected Share Price Decline
- Sarepta Therapeutics: Hold Rating Amid ENDEAVOR Progress and Short-term Challenges
- Sarepta gets FDA approval to test Elevidys regimen in non-ambulant patients